36 related articles for article (PubMed ID: 27354655)
1. YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study.
Li Z; Lu W; Yin F; Huang A
Transl Oncol; 2024 Apr; 45():101965. PubMed ID: 38688048
[TBL] [Abstract][Full Text] [Related]
2. YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Khozooei S; Veerappan S; Toulany M
Strahlenther Onkol; 2023 Dec; 199(12):1110-1127. PubMed ID: 37268766
[TBL] [Abstract][Full Text] [Related]
3. YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.
Zhan Y; Chen X; Zheng H; Luo J; Yang Y; Ning Y; Wang H; Zhang Y; Zhou M; Wang W; Fan S
Sci Rep; 2022 Mar; 12(1):3699. PubMed ID: 35260638
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance.
Alkrekshi A; Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Cell Signal; 2021 Sep; 85():110073. PubMed ID: 34224843
[TBL] [Abstract][Full Text] [Related]
5.
Zhu Z; Zhang X; Zhou Y; Cheng J; Xu Z
Cancer Manag Res; 2020; 12():7189-7197. PubMed ID: 32848471
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway.
Xu WF; Ma YC; Ma HS; Shi L; Mu H; Ou WB; Peng J; Li TT; Qin T; Zhou HM; Fu XQ; Li XH
Cell Cycle; 2019 Dec; 18(24):3472-3490. PubMed ID: 31713447
[TBL] [Abstract][Full Text] [Related]
7. Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis.
Zhang C; Yin T; Tao R; Xiao B; Chen J; Li Z; Miao X; Peng Q; Sun L; Zhang W; Ren J; Zhang Z; Zhang Y; Li X; Zhang W
Cancer Manag Res; 2019; 11():4391-4402. PubMed ID: 31191002
[No Abstract] [Full Text] [Related]
8. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells.
Maier E; Attenberger F; Tiwari A; Lettau K; Rebholz S; Fehrenbacher B; Schaller M; Gani C; Toulany M
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010234
[TBL] [Abstract][Full Text] [Related]
9. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
[TBL] [Abstract][Full Text] [Related]
10. Expanding the map of protein-RNA interaction sites via cell fusion followed by PAR-CLIP.
Hinze F; Drewe-Boss P; Milek M; Ohler U; Landthaler M; Gotthardt M
RNA Biol; 2018 Mar; 15(3):359-368. PubMed ID: 29028411
[TBL] [Abstract][Full Text] [Related]
11. Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.
Vaklavas C; Blume SW; Grizzle WE
Front Oncol; 2017; 7():158. PubMed ID: 28798901
[TBL] [Abstract][Full Text] [Related]
12. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer.
Yan X; Yan L; Zhou J; Liu S; Shan Z; Jiang C; Tian Y; Jin Z
Int J Clin Exp Pathol; 2014; 7(12):8715-23. PubMed ID: 25674237
[TBL] [Abstract][Full Text] [Related]
13. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.
Zhang F; Zhang Y; Zhao W; Deng K; Wang Z; Yang C; Ma L; Openkova MS; Hou Y; Li K
Oncotarget; 2017 May; 8(21):35460-35472. PubMed ID: 28389626
[TBL] [Abstract][Full Text] [Related]
15. YB-1: The key to personalised prostate cancer management?
Bates M; Boland A; McDermott N; Marignol L
Cancer Lett; 2020 Oct; 490():66-75. PubMed ID: 32681926
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
Shiraiwa S; Kinugasa T; Kawahara A; Mizobe T; Ohchi T; Yuge K; Fujino S; Katagiri M; Shimomura S; Tajiri K; Sudo T; Kage M; Kuwano M; Akagi Y
Anticancer Res; 2016 Jul; 36(7):3781-8. PubMed ID: 27354655
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
